New guidance from the World Health Organization (WHO) strongly advises against using the antibody therapies sotrovimab and casirivimab-imdevimab to treat patients with COVID-19.
This guidance, published in the British Medical Journal, replaces previous conditional recommendations for the use of these drugs. It’s based on emerging evidence that they’re not likely to work against current COVID variants such as omicron.
This means that, at least for the time being, there are no recommended antibody therapies to treat COVID. There are, however, still other treatment options. Let’s take a look.